Literature DB >> 9704333

Systemic murine cytomegalovirus infection of mice with retrovirus-induced immunodeficiency results in ocular infection but not retinitis.

R D Dix1.   

Abstract

Experiments were performed to explore the ability of murine cytomegalovirus (MCMV) to disseminate to the eye following intravenous inoculation and to cause infection of ocular tissues and necrotizing retinitis in C57BL/6 mice with retrovirus-induced immunodeficiency syndrome (MAIDS). Although infectious virus could be detected in whole eye homogenates of mice with MAIDS at 10 days after intravenous MCMV inoculation, a recombinant MCMV (RM461) that carries an MCMV IE1 promoter-LacZ insert was used as a tracer virus to confirm direct infection of ocular tissues. Evidence for MCMV replication (determined by RM461-induced expression of beta-galactosidase) was consistently observed in the nonpigmented epithelium of the ciliary body of the eyes of MAIDS animals at 14 days after infection. In sharp contrast, however, the neurosensory retina was spared and necrotizing retinitis failed to develop. These findings demonstrate that systemic MCMV infection of mice with MAIDS results in ocular MCMV infection without development of ocular MCMV disease. Conversion of occult subclinical MCMV infection of ocular tissues to overt clinical MCMV retinitis may require as yet unidentified cofactor(s). Identification of these cofactors could lead to more innovative therapeutic approaches for prevention and/or treatment of CMV retinitis in patients with AIDS.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9704333     DOI: 10.1159/000055488

Source DB:  PubMed          Journal:  Ophthalmic Res        ISSN: 0030-3747            Impact factor:   2.892


  8 in total

1.  Suppressor of Cytokine Signaling 1 (SOCS1) and SOCS3 Are Stimulated within the Eye during Experimental Murine Cytomegalovirus Retinitis in Mice with Retrovirus-Induced Immunosuppression.

Authors:  Hsin Chien; Christine I Alston; Richard D Dix
Journal:  J Virol       Date:  2018-08-29       Impact factor: 5.103

2.  Murine cytomegalovirus (MCMV) spreads to and replicates in the retina after endotoxin-induced disruption of the blood-retinal barrier of immunosuppressed BALB/c mice.

Authors:  Ming Zhang; Hua Xin; Sally S Atherton
Journal:  J Neurovirol       Date:  2005-08       Impact factor: 2.643

3.  Loss of the perforin cytotoxic pathway predisposes mice to experimental cytomegalovirus retinitis.

Authors:  Richard D Dix; Eckhard R Podack; Scott W Cousins
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

4.  Evidence for multiple cell death pathways during development of experimental cytomegalovirus retinitis in mice with retrovirus-induced immunosuppression: apoptosis, necroptosis, and pyroptosis.

Authors:  Hsin Chien; Richard D Dix
Journal:  J Virol       Date:  2012-07-25       Impact factor: 5.103

5.  Inflammation and outer blood-retina barrier (BRB) compromise following choroidal murine cytomegalovirus (MCMV) infections.

Authors:  Jinxian Xu; Xinglou Liu; Juan Mo; Brendan Marshall; Libby Perry; Zheng Dong; Ming Zhang
Journal:  Mol Vis       Date:  2018-05-18       Impact factor: 2.367

Review 6.  SOCS and Herpesviruses, With Emphasis on Cytomegalovirus Retinitis.

Authors:  Christine I Alston; Richard D Dix
Journal:  Front Immunol       Date:  2019-04-11       Impact factor: 7.561

7.  Macrophage activation associated with chronic murine cytomegalovirus infection results in more severe experimental choroidal neovascularization.

Authors:  Scott W Cousins; Diego G Espinosa-Heidmann; Daniel M Miller; Simone Pereira-Simon; Eleut P Hernandez; Hsin Chien; Courtney Meier-Jewett; Richard D Dix
Journal:  PLoS Pathog       Date:  2012-04-26       Impact factor: 6.823

8.  Atypical cytomegalovirus retinal disease in pyroptosis-deficient mice with murine acquired immunodeficiency syndrome.

Authors:  Jessica J Carter; Judee Grace E Nemeno; Jay J Oh; John E Houghton; Richard D Dix
Journal:  Exp Eye Res       Date:  2021-06-05       Impact factor: 3.770

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.